Wegovy Dosing and Administration Guidelines
Introduction to Wegovy
- The American College of Cardiology and other guideline societies recommend initiating Wegovy (semaglutide 2.4 mg) at 0.25 mg once weekly subcutaneously and titrating monthly over 16 weeks to reach the maintenance dose of 2.4 mg weekly, following a structured 5-step protocol 1
Standard Titration Schedule
- The standard titration schedule for Wegovy involves a gradual dose escalation over 16 weeks, with doses of 0.25 mg, 0.5 mg, 1.0 mg, and 1.7 mg once weekly for the first 16 weeks, followed by a maintenance dose of 2.4 mg once weekly 1
Administration Details
- The Mayo Clinic recommends administering Wegovy via subcutaneous injection once weekly, which can be given at any time of day, with or without meals, and should be taken on the same day each week for optimal adherence 2, 3, 1
Missed Dose Management
- If a dose of Wegovy is missed, the patient should resume at the next scheduled dose, and if two consecutive doses are missed, the patient's doctor should use clinical judgment to determine the best course of action, considering the patient's tolerance to the medication 1
Critical Safety Considerations
- The American Heart Association and other guideline societies recommend avoiding the use of Wegovy in patients with a personal or family history of medullary thyroid cancer or multiple endocrine neoplasia syndrome type 2, and monitoring patients for signs of pancreatitis, gallbladder disease, and changes in blood pressure 1, 2, 3
Drug Interactions
- The guideline societies recommend avoiding concurrent use of Wegovy with other GLP-1 receptor agonists or dipeptidyl peptidase-4 inhibitors, and using caution when combining Wegovy with insulin or insulin secretagogues due to an increased risk of hypoglycemia 1, 2